International Journal of Scholarly Resources
Disease Reviews — A Peer-Reviewed Academic Publication
Email: editor@ijsr.org.ng
Website: www.ijsr.org.ng

Gut Microbiota-Immune System Cross-Talk: Mechanisms of Microbial Regulation of Host Immune Responses in Health and Disease

Adedoyin Elizabeth Ayodele
Department of Microbiology, Federal University Oye Ekiti, Nigeria
ayodeleadeli101@gmail.com

Submitted: 1 August 2025 | Published: 12 October 2025

How to cite: Ayodele, A. E. (2025). Gut Microbiota-Immune System Cross-Talk: Mechanisms of Microbial Regulation of Host Immune Responses in Health and Disease. *International Journal of Scholarly Resources*, 18(2), 93-112.

Abstract

THE gut microbiota, a diverse and intricate population of bacteria found in the gastrointestinal tract, interacts with the host immune system in a dynamic and mutually reinforcing manner. In addition to being essential for preserving homeostasis, this cross-talk is linked to the etiology of many illnesses when it is disturbed. This review describes how immune cell function and epithelial integrity are modulated by microbial-associated molecular patterns (MAMPs) and metabolites, such as bile acids, short-chain fatty acids (SCFAs), and tryptophan derivatives, via pattern recognition receptors (PRRs) and other host sensors. In the gut mucosa and throughout the body, we examine how the microbiota informs and regulates the activity of important immune cells, such as T helper 17 (Th17) cells, regulatory T (Treg) cells, and innate lymphoid cells (ILCs). We also examine how immune dysregulation in inflammatory bowel disease (IBD), metabolic diseases, cancer, and neuroinflammatory illnesses is influenced by dysbiosis, a change in the microbial ecosystem. Finally, we discuss new therapeutic approaches that attempt to rebalance immune responses by modifying the gut microbiota, including postbiotics, prebiotics, and next-generation probiotics (live biotherapeutic products). The importance of the gut-immune axis in both health and disease is emphasized in this review, along with the possibility for new treatments that target this interface.

Keywords: Gut Microbiota, Dysbiosis, Immune Regulation, Short-Chain Fatty Acids (SCFAs), Inflammatory Bowel Disease, Pattern Recognition Receptors (PRRs), Postbiotics, Microbial Metabolites

Introduction

ONE of the most intricate and highly populated microbial ecosystems on Earth is the human gastrointestinal tract, which is home to an amazing collection of trillions of bacteria, viruses, fungi, archaea, and eukaryotes known as the gut microbiota Alekseeva et al. (2025). With more than 100 times as many genes encoded as the human genome, this community serves as a multipurpose microbial "organ" that provides a wide range of metabolic, defensive, and structural services vital to host physiology Gilbert et al. (2018). An ongoing and dynamic conversation with the host immune system is crucial to the complex, reciprocal interaction that has been cultivated by the co-evolution of the host and this microbial assemblage Hussain et al. (2025).

The development, instruction, and operation of both innate and adaptive immunity depend on this gut microbiota-immune system axis, which is not only a passive connection but a fundamental component of mammalian biology Acierno et al. (2025). A varied and stable microbial community fosters a state of regulated awareness in eubiosis, a state of health, by establishing tolerance to innocuous food antigens and commensals while also preparing the im-

mune system for robust defense against infections Kim et al. (2025); Suchiita et al. (2025). A complex interchange of molecular signals, including metabolites, immune cell fate and function-influencing effector molecules, and microbial-associated molecular patterns (MAMPs), maintains this fragile equilibrium Montanari et al. (2025).

The extremes of life serve as a clear reminder of the significance of this cross-talk. Microbial colonization is a major factor in the development of a robust epithelial barrier Robertson et al. (2025), balanced differentiation of T helper (Th) cell subsets, and maturation of gut-associated lymphoid tissue (GALT) during the early postnatal period. As demonstrated in germ-free animal models, on the other hand, the lack of a healthy microbiota causes significant immunological deficiencies, such as underdeveloped lymphoid structures, decreased IgA secretion, and an imbalance between pro-inflammatory T helper 17 (Th17) cells and anti-inflammatory regulatory T cells (Tregs) Huang et al. (2025).

Host immunity may suffer significantly if this delicate balance is upset, a condition known as dysbiosis Moustakli et al. (2025). Loss of beneficial microorganisms, a decrease in total microbial diversity, and an increase in pathobionts—commensals that have the potential to be harmful in specific situations—are the hallmarks of dysbiosis. This change results in abnormal immune activation, tolerance loss, and compromised barrier integrity by upsetting the vital signaling networks that preserve homeostasis Han et al. (2025). Such dysregulation is now recognized as a key factor in the pathophysiology of a broad range of illnesses that extend well beyond the gut, rather than just a byproduct. Dysbiosis is now strongly linked to the development and course of autoimmune illnesses, metabolic syndrome, type 2 diabetes, inflammatory bowel disease, celiac disease, allergies, and even neuropsychiatric problems Faysal et al. (2025).

The goal of research has advanced from establishing correlation to conclusively defining mechanism and cause. Modern research using gnotobiotic models, microbial engineering, and multi-omics integration is now clarifying the exact molecular mechanisms by which particular microorganisms and their metabolites, including secondary bile acids, tryptophan derivatives, and short-chain fatty acids (SCFAs), regulate immune responses Beltrán-Velasco & Clemente-Suárez (2025). A new era of therapeutic intervention focused on purposefully altering the microbiota to prevent or treat disease is being ushered in by this improved understanding Yaqub et al. (2025).

Mechanisms of Microbial Immune Regulation

There are several, frequently overlapping ways that the gut microbiota affects the immune system. These can be roughly divided into two categories: direct microbial interactions and indirect effects mediated by microbial metabolites.

Direct Recognition: Pattern Recognition Receptors (PRRs)

To identify conserved microbial-associated molecular patterns (MAMPs), the innate immune system employs a variety of germline-encoded PRRs, including Toll-like receptors (TLRs) and NOD-like receptors (NLRs). Immune development and homeostasis depend on the commensal microbiota's constant, low-level signaling through PRRs.

TLR Signaling

Commensal bacteria provide immunological and epithelial cells in the lamina propria tonic activation of their TLRs. For example, regulatory T cells (Tregs) are stimulated to proliferate and produce anti-inflammatory IL-10 by *Bacteroides fragilis* polysaccharide A (PSA) signals via TLR2 Round & Mazmanian (2010). According to recent research, some commensals' flagellin-mediated TLR5 signaling preserves epithelial integrity and controls the Th17/Treg balance Feng et al. (2023).

NOD2 Signaling

The regulation of gut inflammation depends on the intracellular receptor NOD2, which detects bacterial muramyl dipeptide (MDP). A recent study showed that commensal MDP-induced NOD2 activation in Paneth cells not only triggers the release of antimicrobial peptides but also regulates autophagy, a mechanism essential for reducing inflammation and intracellular infections Huang et al. (2025); Edwards & Brockmann (2025).

Indirect Regulation: Immunomodulatory Microbial Metabolites

The generation of metabolites that permeate host organs and affect immune cell function systemically is arguably the

most important mechanism of microbial immune control.

Short-Chain Fatty Acids (SCFAs)

Bacterial fermentation of dietary fiber yields butyrate, propionate, and acetate. Colonocytes use butyrate as their main energy source, which fortifies the epithelial barrier. As histone deacetylase inhibitors (HDACi), all three SCFAs alter immune cell gene expression epigenetically Lv et al. (2025). They inhibit inflammatory Th17 cell responses and encourage Treg differentiation.

Tryptophan Metabolites

The dietary tryptophan is converted into ligands for the aryl hydrocarbon receptor (AhR) by commensal bacteria such as *Lactobacillus* species. Maintaining innate lymphoid cells type 3 (ILC3) and intraepithelial lymphocytes (IELs), which generate IL-22 to strengthen the mucosal barrier, depends on AhR activation. A recent study discovered that indole-3-carboxylic acid, a novel metabolite generated from tryptophan, strongly activates AhR in dendritic cells, resulting in improved Treg production and defense against experimental autoimmune encephalomyelitis (EAE) Morgan et al. (2023).

Secondary Bile Acids

Lithocholic acid (LCA) and deoxycholic acid (DCA), which are secondary bile acids produced by bacteria, communicate via the G protein-coupled receptor TGR5 and the nuclear receptor FXR Jiang et al. (2025). Strong anti-inflammatory effects are produced by this signaling. According to a recent study, isoallolithocholic acid (isoalloLCA), a particular secondary bile acid, causes mitochondrial reactive oxygen species (mtROS), which in turn stimulate Foxp3 expression, hence expanding Tregs Lee et al. (2024).

Immune Outcomes in Health

During eubiosis, the host immune system receives constant, tonic guidance from the collective signals of a stable and diversified gut microbiota Miniello et al. (2023). This conversation is a lifelong learning process that develops immunological competence from birth, guaranteeing a state of preparedness free from excessive inflammation. This healthy partnership has many benefits and is crucial for overall wellness.

Gut-Associated Lymphoid Tissue (GALT) Development and Maintenance

The appropriate development of the host's immunological architecture is triggered by the initial colonization of the sterile newborn gut Torow et al. (2023). The development and maturation of secondary lymphoid organs in the intestine depend on microbial signals.

Lymphoid Structure Stimulation

Peyer's patches, cryptopatches, and isolated lymphoid follicles (ILFs) form postnatally as a result of MAMPs' constant low-level stimulation of Pattern Recognition Receptors (PRRs) Troch (2025). These structures act as immunological response induction sites. For example, the organization and cellularity of these lymphoid tissues depend on the generation of cytokines (such as IL-7 and lymphotoxin) which are stimulated by signaling via TLRs on stromal cells Zhao et al. (2025). A recent study showed that a particular group of *Clostridium* species is sufficient to cause ILFs to develop in germ-free mice, underscoring the direct influence of specific microorganisms on the immune system Sterling et al. (2022).

Immunoglobulin A (IgA) Production

Secretory IgA is the most prevalent antibody found in mucosal secretions and is a key immunological exclusion mechanism de Fays et al. (2022). Both T-cell-dependent and T-cell-independent class-switch recombination in B cells to IgA is triggered by the microbiome. In the lamina propria, dendritic cells (DCs) sample commensal bacteria and encourage B cells to alter IgA classes, which results in the creation of polyreactive IgA that coats commensals. Instead of killing them, this coating helps keep them contained in the lumen and mucus layer, avoiding systemic translocation and promoting a stable host-commensal connection Pabst & Slack (2020). According to recent research, certain microbial metabolites—most notably SCFAs—increase IgA synthesis by encouraging B-cell differentiation and metabolism, establishing a clear connection between humoral immunity and microbial food fermentation.

Education and Balance of Adaptive Immunity

The adaptive immune system, characterized by highly specialized T and B cells, faces a special challenge in the gut: it must tolerate a wide variety of commensal antigens while

Table 1: Key Microbial Metabolites and Their Immunomodulatory Effects

Metabolite Class	Example Molecules	Primary Producers	Immune Target & Effect
SCFAs	Butyrate, Propionate, Acetate	*Faecalibacterium prausnitzii*, *Roseburia* spp.	HDAC inhibition: enhances epithelial barrier, suppresses NLRP3 inflammasome, encourages Treg differentiation Xiao et al. (2024)
Tryptophan Metabolites	Indole-3-aldehyde, Indole-3-acetic acid	*Lactobacillus* spp., *Bifidobacterium* spp.	AhR activation: maintains ILC3s and IELs, increases IL-22 production Bahman et al. (2024)
Secondary Bile Acids	LCA, isoalloLCA, DCA	*Clostridium* cluster XIVa, XI	FXR/TGR5 signaling: anti-inflammatory; mtROS induction: expands Treg population Zhang et al. (2023)
Polyamines	Spermidine, Spermine	*Bifidobacterium* spp., *Akkermansia muciniphila*	Increase autophagy: decreases intestinal inflammation, improves epithelial barrier Chen et al. (2023)

remaining ready to launch a powerful defense against invasive pathogens. For this crucial balancing act, the gut microbiota serves as the primary teacher, supplying the signals required to educate T cells and direct their development toward suitable functional outcomes Pant et al. (2023).

Induction and Maintenance of Regulatory T Cells (Tregs)

The commensal microbiota's most important immunoregulatory role may be the induction of Foxp3+ regulatory T cells (Tregs) in the lamina propria Round & Mazmanian (2010). Using a variety of suppressive strategies, such as cytolysis, metabolic disruption of effector T cells, and the release of anti-inflammatory cytokines IL-10 and TGF-β, Tregs are the master regulators of immunological tolerance Safinia et al. (2015).

Treg production is encouraged by the microbiota via several unique, frequently cooperative pathways:

Induction by Microbial Antigen: Some commensal bacteria have a strong ability to stimulate Tregs. A group of *Clostridium* clusters IV and XIVa that support colonic Treg differentiation was discovered by pioneering research Atarashi et al. (2011). These bacteria work by causing dendritic and epithelial cells to produce TGF-β, a cytokine essential for Treg lineage commitment and Foxp3 expression. A recent study discovered that a particular surface protein from *Lactobacillus reuteri* directly interacts with dendritic cells' Toll-like receptor 2 (TLR2), causing them to produce retinoic acid Luo et al. (2023), a metabolite of vitamin A, and IL-10, which together produce a tolerogenic environment that promotes Treg differentiation.

Epigenetic Programming Mediated by Metabolite: Microbial metabolites are potent epigenetic regulators of T cell destiny. The short-chain fatty acids (SCFAs) propionate and butyrate directly inhibit histone deacetylases (HDACs) in conventional T lymphocytes. Foxp3 gene expression is significantly increased and the Treg lineage is stabilized as a result of this inhibition, which causes hyperacetylation of histones at the Foxp3 promoter and conserved non-coding sequence (CNS) regions Zhang et al. (2023); Furusawa et al. (2013). Additionally, a recent study clarified that butyrate increases mitochondrial fitness in Tregs, improving their capacity for oxidative phosphorylation and, consequently, their ability to survive and suppress function in the comparatively hypoxic gut environment Nag et al. (2023).

Secondary Bile Acids and Treg Expansion: Microbially modified bile acids are important in addition to SCFAs. It was discovered that certain gut bacteria create the secondary bile acid isoallolithocholic acid (isoalloLCA), which increases the Treg pool by triggering mitochondrial reactive oxygen species (mtROS), which function as signaling molecules to promote Foxp3 expression Zhang et al. (2023).

Regulated T Helper 17 (Th17) Cell Priming

Although Tregs promote tolerance, the ability to regulate inflammation is also necessary for a thorough immune education. The presence of Th17 cells in the intestinal lamina propria at baseline is a sign of a robust immune system Paroni et al. (2023). Because they generate IL-17 and IL-22, which encourage the generation of antimicrobial peptides (such as defensins) by epithelial cells and strengthen barrier function, these cells are essential for defense against fungi and external infections.

Segmented Filamentous Bacteria (SFB) are the archetypal commensal pathobionts that drive Th17 differentiation. SFB adhere intimately to the ileal epithelium, particularly over Peyer's patches Gronke et al. (2023). This adherence triggers a cascade of immune activation: epithelial cells produce serum amyloid A (SAA), which instructs local dendritic cells and macrophages to produce IL-6, IL-23, and TGF-β—the precise cytokine cocktail required to polarize naïve T cells into the Th17 lineage. The presence of SFB-induced Th17 cells is not pathological; instead, it represents a state of heightened alertness that enhances barrier defense and provides cross-protection against systemic pathogens Wang et al. (2019).

Reinforcement of the Epithelial Barrier

The intestinal epithelial barrier is a formidable, single-cell-layer-thick frontier that separates the immense microbial load of the lumen from the sterile, immune-rich environment of the lamina propria. Its integrity is paramount to health, preventing the uncontrolled translocation of microbes and antigens that would trigger pervasive immune activation Abou Diwan et al. (2023).

Stimulation of Mucus Production

The first line of defense is the mucus layer, a viscous gel composed of heavily glycosylated proteins called mucins, primarily MUC2. Goblet cells, responsible for mucin production, are highly responsive to microbial signals. Continuous, low-level stimulation of PRRs, particularly TLRs, drives mucin gene (MUC2) expression and secretion He et al. (2023). The short-chain fatty acid butyrate upregulates MUC2 synthesis via HDAC inhibition, while propionate enhances mucin glycosylation, improving the gel-forming properties of the mucus layer Clark & Mach (2023).

Enhancement of Tight Junction Integrity

Tight junctions seal the paracellular space between adjacent epithelial cells. Butyrate, the preferred energy source for colonocytes, generates ATP to power barrier maintenance, including tight junction assembly Mowat et al. (2023). SCFAs also enhance expression of occludin, claudin-1, and Zonula Occludens-1 (ZO-1) through GPCR (e.g., GPR109a) and AMPK signaling Peng et al. (2009). Acetate promotes rapid repair of wounded epithelial monolayers via GPR43 Canesso et al. (2023).

Production of Antimicrobial Peptides (AMPs)

Paneth cells secrete AMPs like α-defensins and REG3γ in response to PRR signaling by commensal MAMPs Land (2023). Butyrate upregulates cathelicidin (LL-37) expression, enhancing the chemical shield within the mucus layer Korsten et al. (2023).

Modulation of Epithelial Turnover and Repair

Butyrate promotes terminal differentiation and apoptosis in the upper crypt while maintaining a hypoxic environment at the crypt base for stem cell proliferation Inamoto et al. (2023). Tryptophan metabolites act as AhR ligands, promoting goblet cell differentiation and IL-22 production Ahn et al. (2023).

Dysbiosis and Dysregulation in Disease

The state of eubiosis is a cornerstone of health, while dysbiosis disrupts this equilibrium, leading to immune dysregulation and disease Miniello et al. (2023). Dysbiosis involves loss of beneficial microbes, reduced diversity, and expansion of pathobionts, corrupting protective mechanisms Saxami et al. (2023); Chang & Choi (2023).

Inflammatory Bowel Disease (IBD)

IBD, including Crohn's disease and ulcerative colitis, exemplifies dysbiosis-driven immune pathology Thapwong et al. (2023). Depletion of SCFA-producers like *Faecalibacterium prausnitzii* and expansion of pathobionts like adherent-invasive *E. coli* (AIEC) are hallmarks Taylor et al. (2025).

Key mechanisms include:

Table 2: Key Immune Outcomes of a Healthy Gut Microbiota

Immune Component	Outcome of Microbial Influence	Key Microbial Signals & Mechanisms
GALT	Development and maintenance of Peyer's patches, ILFs, cryptopatches	TLR/NOD signaling inducing cytokines (e.g., IL-7, LTα)
Humoral Immunity	Secretory IgA production	T-cell-dependent/independent CSR; SCFAs enhance B-cell metabolism
Tregs	Expansion of Foxp3+ Tregs	SCFAs, PSA (TLR2), isoalloLCA, bacterial antigens
Th17 Cells	Controlled induction for barrier defense	SFB inducing IL-23, IL-1β production
Epithelial Barrier	Enhanced mucus, tight junctions, AMPs	SCFAs, PRR signaling inducing mucin, AMP expression
Innate Immune Cells	Trained immunity	MAMPs (e.g., MDP via NOD2), metabolite-induced epigenetic shifts

- **SCFA Deficiency:** Reduced butyrate impairs colonocyte energy metabolism, weakening tight junctions and increasing intestinal permeability. This allows bacterial translocation and antigen exposure to lamina propria immune cells Hetta et al. (2025).
- **Pathobiont Invasion:** AIEC invades epithelial cells and survives within macrophages, triggering excessive TNF-α and IL-23 production, which drives pathogenic Th1 and Th17 responses Paroni et al. (2023).
- **Loss of Immunoregulation:** Decreased Treg-inducing bacteria leads to diminished IL-10 and TGF-β production, removing the brakes on effector T cell responses Sinha et al. (2023).
- **Altered Bile Acid Metabolism:** Dysbiosis reduces secondary bile acid production, eliminating their anti-inflammatory FXR/TGR5 signaling Sinha et al. (2023).

Metabolic Syndrome and Type 2 Diabetes

Dysbiosis drives obesity, insulin resistance, and type 2 diabetes through multiple mechanisms, collectively termed metabolic endotoxemia Dubey & Singh (2025).

Increased Intestinal Permeability: Reduced SCFA production weakens tight junctions, allowing lipopolysaccharide (LPS) from Gram-negative bacteria to translocate into the bloodstream. Circulating LPS activates TLR4 on adipocytes, hepatocytes, and macrophages, inducing chronic low-grade inflammation characterized by elevated TNF-α, IL-6, and IL-1β Dubey & Singh (2025).

Impaired Incretin Signaling: Dysbiotic microbiota produce less GLP-1-stimulating metabolites, reducing insulin secretion and satiety signaling. Conversely, certain pathobionts produce metabolites like imidazole propionate that directly impair insulin signaling Zhao et al. (2025).

Enhanced Energy Harvest: An obesogenic microbiota profile (increased Firmicutes:Bacteroidetes ratio) extracts more calories from diet, contributing to weight gain and adipose tissue expansion, which further perpetuates inflammation.

Autoimmune Diseases

Beyond the gut, systemic autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis show clear associations with gut dysbiosis Chang & Choi (2023).

Proposed mechanisms include molecular mimicry (bacterial antigens resembling self-antigens), loss of Treg induction leading to breakdown of self-tolerance, and production of pro-inflammatory metabolites that systemically activate autoreactive T cells. For instance, specific *Prevotella* species have been implicated in rheumatoid arthritis through induction of pathogenic Th17 cells Lv et al. (2025).

Cancer

The gut microbiota influences cancer development and progression through both local effects in colorectal cancer and systemic immunomodulation affecting distant tumors.

Pro-tumorigenic Mechanisms: Certain bacteria produce genotoxins that directly damage DNA, while others generate carcinogenic metabolites from dietary precursors. Chronic inflammation driven by dysbiosis creates a tumor-promoting microenvironment rich in reactive oxygen species and growth factors.

Impact on Immunotherapy: Excitingly, specific commensal bacteria enhance anti-tumor immunity and improve responses to immune checkpoint inhibitors. *Akkermansia muciniphila* and certain *Bifidobacterium* species have been associated with better outcomes in melanoma patients receiving anti-PD-1 therapy, likely through enhanced dendritic cell function and CD8+ T cell priming.

Neurological and Psychiatric Disorders

The gut-brain axis, mediated by neural, endocrine, and immune pathways, is profoundly influenced by the microbiota Faysal et al. (2025). Dysbiosis has been implicated in anxiety, depression, autism spectrum disorders, and neurodegenerative diseases.

Microbial metabolites like SCFAs cross the blood-brain barrier and directly affect neuronal function and microglial activation. Dysbiosis-induced systemic inflammation elevates circulating cytokines that signal the brain via vagal afferents and circumventricular organs, altering neurotransmitter systems and behavior. Certain bacteria also directly synthesize neurotransmitters (GABA, serotonin, dopamine) that may influence central nervous system function.

Therapeutic Manipulation of the Gut Microbiota

The mechanistic understanding of microbiota-immune crosstalk has catalyzed development of microbiome-targeted therapeutics. These range from traditional approaches like probiotics to cutting-edge precision interventions.

Probiotics and Next-Generation Probiotics

Traditional Probiotics: Common probiotic strains (*Lactobacillus*, *Bifidobacterium*) have shown modest benefits in certain conditions, particularly antibiotic-associated diarrhea and some cases of IBS. However, their effects are often strain-specific and transient, as they typically do not permanently colonize the gut.

Next-Generation Probiotics (Live Biotherapeutics): These are rationally designed microbial consortia or single strains selected based on mechanistic understanding. Examples include:

- *Faecalibacterium prausnitzii*: A major butyrate producer depleted in IBD. Clinical trials are evaluating its therapeutic potential.
- *Akkermansia muciniphila*: Improves metabolic parameters and enhances cancer immunotherapy responses.
- Engineered strains: Bacteria genetically modified to deliver therapeutic molecules (cytokines, enzymes) directly to the gut.

Prebiotics and Dietary Interventions

Prebiotics are non-digestible food components that selectively stimulate beneficial bacteria. Dietary fiber, resistant starch, and specific oligosaccharides increase SCFA production and Treg induction. Personalized dietary interventions based on individual microbiome composition show promise for metabolic disease management.

Fecal Microbiota Transplantation (FMT)

FMT involves transferring fecal material from a healthy donor to a patient, effectively replacing a dysbiotic community with a healthy one. It is highly effective for recurrent *Clostridioides difficile* infection (>90% cure rate) and is being investigated for IBD, metabolic syndrome, and other conditions. However, safety concerns regarding pathogen transmission and long-term ecological consequences require careful screening and monitoring.

Postbiotics

Postbiotics are non-viable bacterial products (metabolites, cell wall components, secreted factors) that exert beneficial effects without requiring live organisms. Examples include purified SCFAs, bacterial extracellular vesicles, and defined

metabolite cocktails. These offer advantages in terms of safety, stability, and regulatory approval compared to live organisms.

Precision Microbiome Editing

Emerging technologies aim to precisely modify the microbiome:

- **Bacteriophages:** Viruses that specifically target pathobionts while sparing beneficial bacteria.
- **CRISPR-based approaches:** Gene editing to eliminate antibiotic resistance or virulence factors from gut bacteria.
- **Selective antimicrobials:** Narrow-spectrum antibiotics or antimicrobial peptides targeting specific harmful species.

Future Directions and Challenges

Despite remarkable progress, several challenges remain in translating microbiome research into clinical practice:

Individual Variability

Microbiome composition varies dramatically between individuals due to genetics, diet, environment, and medical history. What constitutes a "healthy" microbiome may differ across populations and individuals, necessitating personalized approaches rather than one-size-fits-all interventions.

Causality vs. Correlation

While associations between dysbiosis and disease are abundant, establishing causality remains challenging. Advanced experimental approaches including gnotobiotic models, microbiome-wide association studies (MWAS), and randomized controlled trials with microbiome endpoints are needed.

Mechanistic Complexity

The microbiota-immune interaction involves hundreds of bacterial species producing thousands of metabolites acting on numerous host pathways. Systems biology approaches integrating multi-omics data (metagenomics, metabolomics, immunophenotyping) are essential to capture this complexity.

Safety and Regulation

Live biotherapeutic products face unique regulatory challenges. Long-term safety data, potential for horizontal gene transfer, and unintended ecological consequences must be carefully evaluated. Standardization of microbiome analysis methods is also needed for reproducibility.

Key Research Questions

Critical questions for future investigation include:

- How do early-life microbiome perturbations (cesarean delivery, antibiotics) permanently alter immune programming?
- Can we identify universal "keystone" species essential for health across populations?
- What is the optimal timing and formulation for microbiome-based interventions?
- How do host genetics influence microbiome composition and responses to interventions?
- Can microbiome-targeted therapies prevent disease onset, not just treat established disease?

Conclusion

The cross-talk between the gut microbiota and the host immune system is a cornerstone of human physiology and a critical determinant of health and disease. Over the past decade, research has progressed from simple cataloging of microbial communities to sophisticated mechanistic understanding of how specific bacteria and their metabolites orchestrate immune responses locally and systemically.

In health, a diverse and stable microbiota continuously educates and regulates the immune system, maintaining a state of controlled readiness that tolerates self and commensals while remaining prepared to combat pathogens. This is achieved through multiple mechanisms: direct PRR signaling by MAMPs, metabolite-mediated epigenetic programming of immune cells, and maintenance of epithelial barrier integrity. The result is balanced induction of regulatory T cells and appropriate effector responses, proper development of lymphoid structures, and production of secretory IgA.

When this balance is disrupted by dysbiosis—whether through antibiotics, diet, infection, or other perturba-

Table 3: Therapeutic Strategies Targeting the Gut Microbiota-Immune Axis

Intervention	Mechanism	Clinical Applications	Evidence Level
Traditional Probiotics	Transient colonization, immune modulation	Antibiotic-associated diarrhea, IBS	Moderate (strain-dependent)
Next-Gen Probiotics	Targeted SCFA production, barrier enhancement	IBD, metabolic syndrome, cancer	Emerging (clinical trials)
Prebiotics	Selective stimulation of beneficial bacteria	General health, metabolic disease	Moderate to Strong
FMT	Complete microbiome replacement	*C. difficile* infection, IBD	Strong for CDI; Moderate for IBD
Postbiotics	Direct metabolite/factor delivery	Various inflammatory conditions	Emerging
Bacteriophages	Targeted pathobiont elimination	Antibiotic-resistant infections	Experimental
Dietary Fiber	Increased SCFA production	Metabolic health, inflammation	Strong

tions—the consequences extend far beyond the gut. Immune dysregulation driven by dysbiosis contributes to inflammatory bowel disease, metabolic syndrome, autoimmune diseases, cancer progression, and even neuropsychiatric disorders through the gut-brain axis. The common thread is loss of beneficial microbes and their protective metabolites, expansion of pathobionts, and breakdown of the epithelial barrier, leading to inappropriate immune activation.

This mechanistic insight has opened exciting therapeutic avenues. While challenges remain in standardization, safety evaluation, and personalization, microbiome-targeted interventions—from refined probiotics and prebiotics to fecal microbiota transplantation and precision microbiome editing—represent one of the most promising frontiers in modern medicine. The next generation of therapeutics will likely combine multiple approaches: dietary modification to provide substrates for beneficial microbes, targeted delivery of next-generation probiotics or postbiotics, and selective elimination of pathobionts.

The future of microbiome research lies in integration: combining high-resolution multi-omics profiling with longitudinal clinical studies, gnotobiotic model validation, and artificial intelligence-driven prediction to develop truly personalized interventions. Understanding and harnessing the gut microbiota-immune axis offers unprecedented opportunities to prevent and treat a wide spectrum of diseases, fundamentally transforming our approach to human health.

As we continue to unravel the intricacies of this ancient symbiosis, we must remain mindful that the microbiota is not merely a therapeutic target but a complex ecosystem that has co-evolved with humans over millennia. Our interventions must respect this complexity, aiming not to eliminate or dominate but to restore and maintain the delicate balance that defines health.

Acknowledgments

The author thanks the Department of Microbiology at Federal University Oye Ekiti for institutional support and colleagues for valuable discussions that shaped this review.

Author Contributions

A.E.A. conceived, researched, wrote, and edited the entire manuscript.

Funding

No specific funding was received for this review article.

Conflicts of Interest

The author declares no conflicts of interest.

Data Availability

All data referenced in this review are available in the cited publications. No new primary data were generated for this review.

References

Abou Diwan, M., et al. (2023). Impact of pesticide residues on the gut-microbiota–blood–brain barrier axis. *International Journal of Molecular Sciences*, *24*(7), 6147.

Acierno, C., et al. (2025). Multidrug-resistant infections and metabolic syndrome: An overlooked bidirectional relationship. *Biomedicines*, *13*(6), 1343.

Ahn, Y. M., et al. (2023). Bojungikgi-tang improves skin barrier function and immune response in atopic dermatitis mice fed a low aryl hydrocarbon receptor ligand diet. *Chinese Medicine*, *18*(1), 100.

Alekseeva, A. I., et al. (2025). Traditional fermented milk product from Zambia shifts the gut microbiota to healthier metabolism in a simulated SHIME® model system. *Beneficial Microbes*, *1*(aop), 1–22.

Atarashi, K., et al. (2011). Induction of colonic regulatory T cells by indigenous *Clostridium* species. *Science*, *331*(6015), 337–341.

Bahman, F., et al. (2024). Aryl hydrocarbon receptor: Current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. *Frontiers in Immunology*, *15*, 1421346.

Beltrán-Velasco, A. I., & Clemente-Suárez, V. J. (2025). Harnessing gut microbiota for biomimetic innovations in health and biotechnology. *Biomimetics*, *10*(2), 73.

Brockmann, L., et al. (2023). Intestinal microbiota-specific Th17 cells possess regulatory properties and suppress effector T cells via c-MAF and IL-10. *Immunity*, *56*(12), 2719–2735.

Canesso, M. C. C., et al. (2023). Dietary fiber improves skin wound healing and scar formation through the metabolite-sensing receptor GPR43. *Journal of Investigative Dermatology*, *143*(9), 1850–1854.

Chang, S. H., & Choi, Y. (2023). Gut dysbiosis in autoimmune diseases: Association with mortality. *Frontiers in Cellular and Infection Microbiology*, *13*, 1157918.

Chen, S. L., et al. (2023). How autophagy, a potential therapeutic target, regulates intestinal inflammation. *Frontiers in Immunology*, *14*, 1087677.

Clark, A., & Mach, N. (2023). The gut glycome-microbiota axis: A missing key to optimizing endurance fitness. *Frontiers in Physiology*, *14*, 1284423.

de Fays, C., et al. (2022). Secretory immunoglobulin A immunity in chronic obstructive respiratory diseases. *Cells*, *11*(8), 1324.

Dubey, A. K., & Singh, S. K. (2025). Dietary strategies for metabolic syndrome: Enhancing gut microbiome health, postbiotics, and innovative supplements. In *Gut Microbiome and Environmental Toxicants* (pp. 69–81). Singapore: Springer Nature.

Edwards, M., & Brockmann, L. (2025). Microbiota-dependent modulation of intestinal anti-inflammatory CD4+ T cell responses. *Seminars in Immunopathology*, *47*(1), 23.

Faysal, M., et al. (2025). The microbiota-gut-brain connection: A new horizon in neurological and neuropsychiatric disorders. *CNS Neuroscience & Therapeutics*, *31*(9), e70593.

Feng, S., et al. (2023). TLR5 signaling in the regulation of intestinal mucosal immunity. *Journal of Inflammation Research*, *16*, 2491–2501.

Furusawa, Y., et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*, *504*(7480), 446–450.

Gilbert, J. A., et al. (2018). Current understanding of the human microbiome. *Nature Medicine*, *24*(4), 392–400.

Gronke, K., et al. (2023). Human Th17- and IgG3-associated autoimmunity induced by a translocating gut pathobiont. *bioRxiv*, 2023-06.

Han, L., et al. (2025). Immune tolerance regulation is critical to immune homeostasis. *Journal of Immunology Research*, *2025*(1), 5006201.

He, C., et al. (2023). View from the biological property: Insight into the functional diversity and complexity of the gut mucus. *International Journal of Molecular Sciences*, *24*(4), 4227.

Hetta, H. F., et al. (2025). Gut virome: New key players in the pathogenesis of inflammatory bowel disease. *World Journal of Methodology*, *15*(2), 92592.

Huang, X., et al. (2025). Human microbiota-associated animal models: A review. *Frontiers in Cellular and Infection Microbiology*, *15*, 1644187.

Hussain, M. S., et al. (2025). Introduction to microbiome. In *Gut Microbiome and Environmental Toxicants* (pp. 23–40). CRC Press.

Inamoto, T., et al. (2023). Short-chain fatty acids stimulate dendrite elongation in dendritic cells by inhibiting histone deacetylase. *The FEBS Journal*, *290*(24), 5794–5810.

Jiang, J., et al. (2025). Novel approaches in glucose and lipid metabolism disorder therapy: Targeting the gut microbiota–bile acid axis. *Biology*, *14*(7), 802.

Kim, H., et al. (2025). Understanding the diversity and roles of the canine gut microbiome. *Journal of Animal Science and Biotechnology*, *16*(1), 95.

Korsten, S. G., et al. (2023). Butyrate protects barrier integrity and suppresses immune activation in a Caco-2/PBMC co-culture model. *Nutrients*, *15*(12), 2760.

Land, W. G. (2023). The DAMP-driven host immune defense program against pathogens. In *Damage-Associated Molecular Patterns in Human Diseases* (pp. 203–284). Cham: Springer.

Lee, M. H., et al. (2024). How bile acids and the microbiota interact to shape host immunity. *Nature Reviews Immunology*, *24*(11), 798–809.

Luo, Z., et al. (2023). *Limosilactobacillus reuteri* in immunomodulation: Molecular mechanisms and potential applications. *Frontiers in Immunology*, *14*, 1228754.

Lv, J., et al. (2025). Role of the intestinal flora-immunity axis in the pathogenesis of rheumatoid arthritis. *Molecular Biology Reports*, *52*(1), 1–11.

Miniello, V. L., et al. (2023). Gut immunobiosis and biomodulators. *Nutrients*, *15*(9), 2114.

Montanari, E., et al. (2025). Biofilm formation by the host microbiota: A protective shield against immunity and its implication in cancer. *Molecular Cancer*, *24*(1), 148.

Morgan, E. W., et al. (2023). Contribution of circulating host and microbial tryptophan metabolites toward AhR activation. *International Journal of Tryptophan Research*, *16*, 11786469231182510.

Moustakli, E., et al. (2025). Gut microbiome dysbiosis and its impact on reproductive health: Mechanisms and clinical applications. *Metabolites*, *15*(6), 390.

Mowat, C., et al. (2023). Short chain fatty acids prime colorectal cancer cells to activate antitumor immunity. *Frontiers in Immunology*, *14*, 1190810.

Nag, S., et al. (2023). Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases. *Immunity, Inflammation and Disease*, *11*(12), e1121.

Pabst, O., & Slack, E. (2020). IgA and the intestinal microbiota: The importance of being specific. *Mucosal Immunology*, *13*(1), 12–21.

Pant, A., et al. (2023). Host microbiome in tuberculosis: Disease, treatment, and immunity perspectives. *Frontiers in Microbiology*, *14*, 1236348.

Paroni, M., et al. (2023). An intestinal Th17 subset is associated with inflammation in Crohn's disease and activated by adherent-invasive *Escherichia coli*. *Journal of Crohn's and Colitis*, *17*(12), 1988–2001.

Peng, L., et al. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *Journal of Nutrition*, *139*(9), 1619–1625.

Robertson, K. M., et al. (2025). Microbial metabolites–a key to address gut inflammation and barrier dysfunction in the premature infant. *Gut Microbes*, *17*(1), 2551117.

Round, J. L., & Mazmanian, S. K. (2010). Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proceedings of the National Academy of Sciences*, *107*(27), 12204–12209.

Safinia, N., et al. (2015). Regulatory T cells: Serious contenders in the promise for immunological tolerance in transplantation. *Frontiers in Immunology*, *6*, 438.

Saxami, G., et al. (2023). The gut–organ axis within the human body: Gut dysbiosis and the role of prebiotics. *Life*, *13*(10), 2023.

Sinha, S., et al. (2023). Altered bile acid pool in Crohn's disease patients. *Gastroenterology*, *164*(6), 987–989.

Sterling, K. G., et al. (2022). Mucosal immunity and the gut-microbiota-brain-axis in neuroimmune disease. *International Journal of Molecular Sciences*, *23*(21), 13328.

Suchiita, A., et al. (2025). Harmony within: Unravelling the microbiome–immune system symbiosis for health. *Advanced Gut & Microbiome Research*, *2025*(1), 9927379.

Taylor, H., et al. (2025). Autoimmunity in inflammatory bowel disease: A holobiont perspective. *Current Opinion in Immunology*, *94*, 102557.

Thapwong, P., et al. (2023). A systematic review of the impact of inflammatory bowel disease (IBD) on family members. *Journal of Clinical Nursing*, *32*(9–10), 2228–2238.

Torow, N., et al. (2023). Programmed and environmental determinants driving neonatal mucosal immune development. *Immunity*, *56*(3), 485–499.

Troch, K. F. (2025). Unveiling a crucial role for ILC2s in B1 cell regulation via IL-5. *Doctoral dissertation*.

Wang, Y., et al. (2019). Induction of intestinal Th17 cells by flagellins from segmented filamentous bacteria. *Frontiers in Immunology*, *10*, 2750.

Xiao, J., et al. (2024). Crosstalk between hypoxia-inducible factor-1alpha and short-chain fatty acids in inflammatory bowel disease. *Frontiers in Immunology*, *15*, 1385907.

Yaqub, M. O., et al. (2025). Microbiome-driven therapeutics: From gut health to precision medicine. *Gastrointestinal Disorders*, *7*(1), 7.

Zhang, Y., et al. (2023). Effect of gut flora mediated-bile acid metabolism on intestinal immune microenvironment. *Immunology*, *170*(3), 301–318.

Zhang, Z., et al. (2023). Treg plasticity and human diseases. *Inflammation Research*, *72*(12), 2181–2197.

Zhao, R., & Gao, D. (2025). Innate immunity and tertiary lymphoid structures. *Immunological Reviews*, *332*(1), e70052.